Integration of home-monitoring of macular disease in NHS

将黄斑疾病家庭监测纳入 NHS

• 批准号: 83506
• 金额: $ 7.56万
• 依托单位: OKULO LTD
• 依托单位国家: 英国
• 项目类别: Small Business Research Initiative
• 财政年份: 2020
• 资助国家: 英国
• 起止时间: 2020 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=83506
• 关键词: Integration; home; monitoring; macular; disease

This project is to drive the development of a technological system and corresponding patient pathway to allow AI-driven home-monitoring of vision for patients who would otherwise have had to come for in-person hospital eye clinic appointments, specifically for those living with macular disease. This project will develop diagnostic biomarkers from app data and research ways to optimise their uptake in the NHS and beyond. This will increase both the environmental sustainability and the financial sustainability of the NHS. This responds to the acute COVID challenge that we now need to triage/monitor vision away from hospital clinics. The mass cancellation of in-person appointments means that our patient population face sight loss if a deterioration in their condition is not picked up early enough in time for treatment. In the project we will work closely with Nottingham hospital, City University and with charity Macular Society. The proposed project isn't just about developing connected and clever technology, but it's about co-designing with patients and their families, and doctors, nurses and hospital administration systems a brand new digital pathway of care that will revolutionise the experience of eye care for all of us when we need it.

该项目旨在推动技术系统和相应患者路径的开发，以允许人工智能驱动的家庭视力监测患者，否则他们必须亲自前往医院眼科诊所预约，特别是那些患有黄斑疾病的患者。该项目将从应用程序数据和研究方法中开发诊断生物标志物，以优化其在NHS及其他领域的吸收。这将提高NHS的环境可持续性和财政可持续性。这是对急性COVID挑战的回应，我们现在需要从医院诊所分流/监测视力。大规模取消面对面预约意味着，如果我们的患者病情恶化没有及时得到治疗，他们将面临视力丧失。在这个项目中，我们将与诺丁汉医院、城市大学和慈善机构黄斑协会密切合作。拟议的项目不仅仅是开发连接和智能技术，而是与患者及其家属，医生，护士和医院管理系统共同设计一种全新的数字护理途径，这将在我们需要时彻底改变我们所有人的眼科护理体验。